Francisco Caravaca1, Boris Gonzales2, Miguel Ángel Bayo2, Enrique Luna2. 1. Servicio de Nefrología, Hospital Infanta Cristina, Badajoz, España. Electronic address: fcaravacam@senefro.org. 2. Servicio de Nefrología, Hospital Infanta Cristina, Badajoz, España.
Abstract
INTRODUCTION: Chronic musculoskeletal pain (CMP) is a very common symptom in patients with chronic kidney disease (CKD), and is associated with a significant deterioration in quality of life. AIMS: To determine the prevalence and clinical characteristics associated with CMP in patients with advanced CKD not on dialysis, and to analyse their relation with other uraemic symptoms and their prognosis significance. MATERIAL AND METHODS: Cross-sectional study to analyse the uraemic symptoms of an unselected cohort of patients with CKD stage 4-5 pre-dialysis. In order to characterise patients with CMP, demographic and anthropometric data were collected, as well as data on comorbidities and kidney function. In addition, inflammatory parameters, uric parameters, bone mineral metabolism including 25-hydroxycholecalciferol (25-OHCC), creatine kinase and drugs of potential interest including allopurinol, statins and erythropoiesis-stimulating agents were recorded. RESULTS: The study group consisted of 1169 patients (mean age 65±15 years, 54% male). A total of 38% of patients complained of CMP, and this symptom was more prevalent in women than in men (49 vs. 28%; P<.0001). Muscle weakness, pruritus, muscle cramps, ecchymosis, insomnia, oedema and dyspnoea were the most common symptoms associated with CMP. There were no significant associations between serum levels of creatine kinase, 25-OHCC, treatment with allopurinol, statins or erythropoiesis-stimulating agents and CMP. The female gender, elderly age, obesity, comorbidity (mainly diabetes, heart failure or COPD), and elevated levels of inflammatory markers (C-reactive protein and non-neutrophilic leukocytes) were the best determinants of CMP. While patients with CMP showed a worse survival rate, a multivariate analysis adjusted for demographic data ruled out the independent association of CMP with mortality. CONCLUSIONS: CMP is highly prevalent in patients with advanced CKD and is associated with other common symptoms of chronic uraemia. As with the general population, elderly age, the female gender, obesity and some comorbid conditions are the best determinants of CMP. Increased inflammatory markers commonly observed in patients with CMP may have a relevant role in its pathogenesis.
INTRODUCTION:Chronic musculoskeletal pain (CMP) is a very common symptom in patients with chronic kidney disease (CKD), and is associated with a significant deterioration in quality of life. AIMS: To determine the prevalence and clinical characteristics associated with CMP in patients with advanced CKD not on dialysis, and to analyse their relation with other uraemic symptoms and their prognosis significance. MATERIAL AND METHODS: Cross-sectional study to analyse the uraemic symptoms of an unselected cohort of patients with CKD stage 4-5 pre-dialysis. In order to characterise patients with CMP, demographic and anthropometric data were collected, as well as data on comorbidities and kidney function. In addition, inflammatory parameters, uric parameters, bone mineral metabolism including 25-hydroxycholecalciferol (25-OHCC), creatine kinase and drugs of potential interest including allopurinol, statins and erythropoiesis-stimulating agents were recorded. RESULTS: The study group consisted of 1169 patients (mean age 65±15 years, 54% male). A total of 38% of patients complained of CMP, and this symptom was more prevalent in women than in men (49 vs. 28%; P<.0001). Muscle weakness, pruritus, muscle cramps, ecchymosis, insomnia, oedema and dyspnoea were the most common symptoms associated with CMP. There were no significant associations between serum levels of creatine kinase, 25-OHCC, treatment with allopurinol, statins or erythropoiesis-stimulating agents and CMP. The female gender, elderly age, obesity, comorbidity (mainly diabetes, heart failure or COPD), and elevated levels of inflammatory markers (C-reactive protein and non-neutrophilic leukocytes) were the best determinants of CMP. While patients with CMP showed a worse survival rate, a multivariate analysis adjusted for demographic data ruled out the independent association of CMP with mortality. CONCLUSIONS: CMP is highly prevalent in patients with advanced CKD and is associated with other common symptoms of chronic uraemia. As with the general population, elderly age, the female gender, obesity and some comorbid conditions are the best determinants of CMP. Increased inflammatory markers commonly observed in patients with CMP may have a relevant role in its pathogenesis.
Authors: Gang Jee Ko; Yoshitsugu Obi; Tae Ik Chang; Melissa Soohoo; Rieko Eriguchi; Soo Jeong Choi; Daniel L Gillen; Csaba P Kovesdy; Elani Streja; Kamyar Kalantar-Zadeh; Connie M Rhee Journal: J Am Med Dir Assoc Date: 2019-01-25 Impact factor: 4.669
Authors: Cristina Vasilica; Tom Oates; Christian Clausner; Paula Ormandy; Jonathan Barratt; Matthew Graham-Brown Journal: Kidney Int Rep Date: 2021-03-02
Authors: Marijn F Stokman; Bert van der Zwaag; Nicole C A J van de Kar; Mieke M van Haelst; Albertien M van Eerde; Joost W van der Heijden; Hester Y Kroes; Elly Ippel; Annelien J A Schulp; Koen L van Gassen; Iris A L M van Rooij; Rachel H Giles; Philip L Beales; Ronald Roepman; Heleen H Arts; Ernie M H F Bongers; Kirsten Y Renkema; Nine V A M Knoers; Jeroen van Reeuwijk; Marc R Lilien Journal: Pediatr Nephrol Date: 2018-07-05 Impact factor: 3.714
Authors: Thomas J Wilkinson; Daniel G D Nixon; Jared Palmer; Courtney J Lightfoot; Alice C Smith Journal: BMC Nephrol Date: 2021-04-22 Impact factor: 2.388